Home
Dr. Falk Pharma

Dr. Falk Pharma Market Share Analysis for July 2026

Health > Health Conditions and Concerns

Domaindrfalkpharma.de

Year Founded--

Employees1001 - 5000

Annual Revenue$15M - $25M

Dr. Falk Pharma

Dr. Falk Pharma (including company regionals)

drfalkpharma.de

See more website traffic and engagement information

Dr. Falk Pharma Revenue up to July 2026 is 15M - 25M

revenue generated by Dr. Falk Pharma top domains

Dr. Falk Pharma top domains revenue over 3 years

Revenue for Dr. Falk Pharma top domains

drfalkpharma.de15M - 25M

See more with Sales Intelligence

Total visits to Dr. Falk Pharma's top domains

Understand Dr. Falk Pharma market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Dr. Falk Pharma's top domains

Analyze Dr. Falk Pharma engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Dr. Falk Pharma's top domains

See how Dr. Falk Pharma keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Dr. Falk Pharma top competitors by domain

Top similar sites in July 2026, ranked by their affinity

abbott.comCompany NameAbbott Employees> 10001HQUnited States, Illinois, ChicagoAnnual revenue> $1BTotal visits1.6MHealth > Health - Other

Top technologies used by Dr. Falk Pharma

These are the website technologies, by industry, used by Dr. Falk Pharma top domains

Payment & Currencies (25)

Cart Functionality

Advertising (3)

PubMatic

Conversion & Analytics (3)

Google Analytics

Widget (3)

Google Maps

More Technologies

11

See all

News & Signals from Dr. Falk Pharma

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsDr. Falk Pharma GmbH is developing ZED1227/TAK-227.Japanese pharmaceutical firm Takeda, and Germany-based Zedira and Dr. Falk Pharma GmbH have announced a collaboration and licensing agreement to develop ZED1227/TAK-227, a Phase 2b investigational therapy for the treatment of celiac disease.

NewsPrometheus Biosciences, Inc. partners with Dr. Falk Pharma GmbH.Prometheus Biosciences has entered into an agreement with Dr. Falk Pharma for the development and commercialization of Pr600, a novel precision antibody, for the treatment of inflammatory bowel disease (IBD).